New Prediction Model Identifies Ocular Myasthenia Gravis Patients Likely to Achieve Remission

Researchers translated specific ocular examination findings into a practical prognostic tool that clinicians can use to predict which patients with ocular myasthenia gravis are likely to achieve minimal manifestation status or better within 12 months. This information can help inform targeted treatment strategies, they argue. Photo: Dennis Mathews, OD. Click image to enlarge. A new prognostic model using ocular and systemic measures can identify which patients with ocular myasthenia gravis (OMG) are likely to reach minimal manifestation status (MMS) within one year, researchers report. While MMS is distinct from complete stable remission, the clinical benchmark indicates that a patient has no functional limitations from myasthenia gravis and could help inform personalized management strategies. Investigators reviewed 216 patients seen between 2020 and 2023 at a single tertiary eye center. After applying exclusion criteria, they analyzed 126 newly diagnosed OMG patients followed for at least 12 months. Collected data included ophthalmic measures (graded ptosis, extraocular motility and prism-measured ocular deviation), laboratory and imaging tests (AChR antibody, thymus CT, thyroid function and ultrasound) and treatments received (pyridostigmine, corticosteroids, immunosuppressants). The outcome was achievement of MMS or better at one year; nearly half of patients (48.4%) met that endpoint.Using a selection procedure known as LASSO (Logistic and Least Absolute Shrinkage and Selection Operator), researchers were able to identify five key variables predictive of achieving MMS status within one year: Antibody (anti-AChR) positivity (odds ratio, OR: 0.15). This marker was strongly associated with lower odds of MMS.Ocular deviation angle (per 10 prism diopters; OR: 0.71). A larger deviation predicted a worse outcome.Disease duration (per year; OR: 0.80). Longer time to diagnosis was linked to lower remission odds.Thyroid ultrasound abnormality (OR: 0.37). Structural thyroid changes reduced the chance of MMS.Corticosteroid therapy (OR: 3.03). Receiving steroids increased the likelihood of MMS after adjustment.The logistic nomogram incorporating these five factors achieved an area under the ROC curve of 0.889 in the training cohort and 0.813 in internal validation, reflecting a high prediction ability.“Using this model to predict OMG patients’ progress is convenient and can be widely extended to neurological, as well as ophthalmic, healthcare settings,” the researchers concluded in their paper. “Furthermore, based on prognostic predictions, early efforts can be made to develop therapeutic interventions that are more specific to individual patient disease progression and clinical needs.”Given the single-center study design and short follow-up period, the researchers caution that “future validation in larger OMG cohorts is essential to enhance the model’s robustness and clinical applicability.” Click here for the source. Cai Y, Tang T, Peng S, et al. Identification of ocular and systemic predictors and development of a prediction model in ocular myasthenia gravis. Transl Vis Sci Technol. 2026;15(5):11. This article was developed by the editorial staff in conjunction with experts in the field. In the process, AI may have been among the editorial tools used to meet the goals of human editors, who approved all content.